Results 201 to 210 of about 91,776 (288)

Identification of Potential Biomarkers for Ulcerative Colitis and Analysis of Immune Cell Infiltration: A Study Based on Data‐Independent Acquisition Proteomics and the GEO Public Database

PROTEOMICS – Clinical Applications, Volume 20, Issue 6, November 2026.
ABSTRACT Background Ulcerative colitis (UC) is a challenging inflammatory bowel disease characterized by chronic inflammation of the colon's mucosal layer. Despite advances in medical research, UC lacks definitive diagnostic tests and targeted treatments.
Shuai Wang, Hualiang Deng, Dajuan Sun
wiley   +1 more source

Engineered SERPINE1 Overexpression Activates the pp53/p21 Pathway and Promotes a Growth-Restricted, Migratory Phenotype in KRAS-Transformed Renal Proximal Tubular Cells. [PDF]

Biomolecules
Nuha N, Higgins CE, Higgins SP, Samarakoon R, Higgins PJ.   +4 more
europepmc   +1 more source

A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour‐targeting function

British Journal of Pharmacology, Volume 183, Issue 22, Page 6685-6703, November 2026.
Abstract Background and Purpose Site‐specific antibody modification is a useful chemical strategy to elaborate antibody therapeutic function. Conventional lysine‐ or cysteine‐based conjugation methods generate heterogeneous products, while protein engineering approaches are resource‐intensive.
Karolina Krygier, Sandra Szu‐Wei Hwang, Anthony F. Rullo   +2 more
wiley   +1 more source

Beyond Direct Fibrinolysis: Novel Approaches to Thrombolysis. [PDF]

Pharmaceuticals (Basel)
Shibeko AM, Nikitin NS, Podoplelova NA, Manuvera VA, Lazarev VN.   +4 more
europepmc   +1 more source

SERPINE1 Alternative Polyadenylation Influences Gastric Cancer Prognosis via N6‐Methyladenosine Modification

Cancer Science, Volume 117, Issue 11, Page 3132-3145, November 2026.
Multi‐omics integration of the transcriptomic APA landscape and m6A modifications identifies key prognostic genes. Their biological functions and molecular mechanisms in promoting tumor progression are comprehensively validated through in vitro assays. ABSTRACT Alternative polyadenylation (APA) and N6‐methyladenosine (m6A) methylation are critical post‐
Zhuoyi Wu, Ruyun Xu, Ju Fang, Bing Liu, Cao Zhang, Shangxin Zhang, Jing Ni   +6 more
wiley   +1 more source

A working model for CCN3 C-terminal domain-mediated transcriptional modulation of the plasminogen activation system. [PDF]

J Cell Commun Signal
Perbal B.
europepmc   +1 more source

Prospective Study of Targeted Busulfan–Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Genetic Rare Diseases

European Journal of Haematology, Volume 117, Issue 5, Page 1369-1377, November 2026.
ABSTRACT Objectives Genetic rare diseases (GRDs), including chronic granulomatous disease, familial hemophagocytic lymphohistiocytosis, and congenital neutropenia, often require hematopoietic stem cell transplantation (HSCT) as the only curative option.
Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hyun Jin Park, Kyung‐Sang Yu, In‐Jin Jang, Hyoung Jin Kang   +6 more
wiley   +1 more source

Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice.

Blood, 2015
Hijazi N, Abu Fanne R, Abramovitch R, Yarovoi S, Higazi M, Abdeen S, Basheer M, Maraga E, Cines DB, Higazi AA.   +9 more
europepmc   +1 more source

Physiopathology of fibrinolysis in sepsis-induced disseminated intravascular coagulation: Emerging mechanisms and pharmacological targets. [PDF]

Ann Intensive Care
Tschirhart M, Martin M, Curtiaud A, Angles-Cano E, Meziani F, Toti F, Helms J.   +6 more
europepmc   +1 more source

Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk

Journal of Internal Medicine, Volume 300, Issue 5, Page 590-609, November 2026.
Abstract Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome, affects 10%–13% of women of reproductive age and remains underdiagnosed despite its substantial health burden. The introduction of the new PMOS nomenclature in 2026 reflects a fundamental shift in understanding the condition as a lifelong endocrine ...
Maria Forslund, Johanna Melin, Anju E. Joham, Terhi T. Piltonen, D. Aled Rees, Helena J. Teede   +5 more
wiley   +1 more source